Wugen
Biotechnology company developing next-generation cell therapies using memory natural killer (NK) cells for the treatment of cancer. Part of the Abingworth portfolio.
Website
https://www.wugen.comLocation
St. Louis, Missouri, USA
Founded
2018
Investors
1
Categories
biotech, cell-therapy, oncology, nk-cells
Notes
Wugen is a biotechnology company developing next-generation cell therapies using memory natural killer (NK) cells for the treatment of cancer. The company is headquartered in St. Louis, Missouri.
NK cells are immune cells that can recognize and kill cancer cells without prior sensitization. Wugen's approach focuses on memory NK cells, which have enhanced persistence and anti-tumor activity compared to conventional NK cells. This technology offers potential advantages:
- Off-the-shelf cell therapy (allogeneic)
- Enhanced persistence and efficacy
- Potential for broader patient access
- Applications in hematologic malignancies and solid tumors
The company is part of the Abingworth portfolio.
Team
- Todd Fehniger, M.D., Ph.D. - Co-founder & Chief Scientific Officer
- Washington University faculty
Additional Research Findings
- Part of Abingworth portfolio
- Memory NK cell technology
- Allogeneic cell therapy approach
- Oncology focus
- St. Louis, Missouri headquarters
- Founded in 2018
- Washington University spinout
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Abingworth | London, UK / Boston, USA | biotech-focused | seedseries-a+3 | 34 |